<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812290</url>
  </required_header>
  <id_info>
    <org_study_id>ATAGC 03</org_study_id>
    <nct_id>NCT02812290</nct_id>
  </id_info>
  <brief_title>Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation, a Multicenter Study</brief_title>
  <acronym>INTERLUNG</acronym>
  <official_title>Multi-Centric Observational Study to Analyze the Diagnostic Molecular Features in the Clinical Setting of Lung Allograft Biopsies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To evaluate the potential impact of molecular phenotyping of transbronchial
      biopsies in lung transplant recipients with allograft dysfunction, and the potential for
      developing a safer endobronchial mucosal biopsy format.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard for biopsy-based diagnoses of dysfunction of lung transplants is the
      International Society of Heart and Lung Transplantation (ISHLT) classification applied to
      transbronchial biopsies, which represents an arbitrary international consensus. Recent
      data-driven approaches using molecular and conventional technologies indicate that this
      system produces frequently incorrect diagnoses with potential harm to patients due to
      inappropriate treatment. especially in relationship to the correct diagnosis of chronic lung
      allograft dysfunction is a pressing need. To address this unmet need and improve diagnostics
      in the area of organ transplantation, the Alberta Transplant Applied Genomics Centre (ATAGC,
      University of Alberta) has developed a new diagnostic system - the Molecular Microscope™
      Diagnostic System (MMDx™) that interprets biopsies in terms of their molecular phenotype. The
      MMDx™, developed first in kidney transplant biopsies with well established phenotypes, will
      now be adapted to lung transplant transbronchial biopsies (TBBs). Microarray analysis of lung
      allograft biopsy specimens will be compared to conventional allograft phenotyping, including
      clinical, physiologic, radiographic and histological assessment. The present study will use
      the MMDx™ system to assess and report TBBs, and validate and refine this system in 300
      unselected prospectively collected lung TBBs. A subset of the study will examine the third
      bifurcation mucosal endobronchial biopsies (3BMBs) paired with TBBs from 50 patients to see
      if the safer 3BMBs can substitute for the TBB to be used by MMDx™.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assign molecular scores (probability) of lung transplant disease in a reference set of 300 transbronchial biopsies.</measure>
    <time_frame>two years</time_frame>
    <description>Create molecular classifier that predicts antibody mediated and T cell mediated rejection, and chronic allograft dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assign molecular scores (probability) of lung transplant disease in a reference set of 50 mucosal endobronchial biopsies.</measure>
    <time_frame>two years</time_frame>
    <description>Create molecular classifier that predicts antibody mediated and T cell mediated rejection, and chronic allograft dysfunction.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Lung Transplant Rejection</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lung transplant biopsy bites.</intervention_name>
    <description>In the second phase of the study, we will collect two biopsy bites from the same patient to assess tissue sampling variability.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lung transplant biopsies taken as per local standard of care.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with functioning lung transplant biopsied to determine their graft dysfunction of
        to confirm good function as per standard of care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All lung transplant recipients undergoing a biopsy as determined by their surgeon or
             physician.

        Exclusion Criteria:

        Patients who declined participation or unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip F Halloran, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine and Dentistry, University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad S Famulski, PhD</last_name>
    <phone>1 780 492 1725</phone>
    <email>konrad@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Polakowski, PhD</last_name>
    <phone>1 780 492 5091</phone>
    <email>polakows@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>MD 21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina L Timofte, MD</last_name>
      <phone>216-334-7534</phone>
      <email>itimofte@medicine.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Irina L Timofte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Pulmonary and Critical Care, Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>MO 63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Kreisel, MD, PhD</last_name>
      <phone>314-362-6021</phone>
      <email>kreiseld@wudosis.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Kreisel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elbert Trulock, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramsey Hachem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>MD 21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Jo Levine, MD</last_name>
      <email>levinedj@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Jo Levine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital, Monash University</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glen Westall, MD, PhD</last_name>
      <phone>+61 3 9076 2405</phone>
      <email>g.westall@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Glen Westall, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greg Snell, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Thoracic Surgery, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Klepetko, MD, PhD</last_name>
      <phone>+43-1-40400-5644</phone>
    </contact>
    <investigator>
      <last_name>Walter Klepetko, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Jaksch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Transplant Applied Genomics Centre, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konrad S Famulski, PhD</last_name>
      <phone>1 780 492 1725</phone>
      <email>konrad@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Philip F Halloran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kieran Halloran, MD</last_name>
      <phone>1 780 492 2691</phone>
      <email>kieran.halloran@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Kieran Halloran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network, Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaf Keshavjee, MD, MSc</last_name>
      <phone>1 416-340-3863</phone>
      <email>shaf.keshavjee@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Shaf Keshavjee, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Juvet, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Philip Halloran</investigator_full_name>
    <investigator_title>Distinguished Professor</investigator_title>
  </responsible_party>
  <keyword>antibody mediated rejection, T cell mediated rejection</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

